Obinutuzumab interactions

Conditions

Conditions in which Obinutuzumab needs care, as documented in this source.

• Hepatitis B

  Major

  The use of anti-CD20 antibodies has caused reactivation of hepatitis B virus, in some cases with fatal outcomes. It is recommended to screen all patients for hepatitis B virus infection before initiating treatment. Monitor patients during, and after several months for hepatitis B virus infection according to clinical practice. Discontinue these agents immediately and institute appropriate treatment if patients develop reactivation of hepatitis B virus while on therapy.

  2 sources

  1. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline (2009):
  2. "Product Information. Gazyva (obinutuzumab)." Genentech (2013):

• Leukoencephalopathy, Progressive Multifocal

  Major

  Serious infections, including reactivation of viral infections, have been reported with the use of anti-CD20 antibodies. JC virus infections resulting in progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with these agents. A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations, and a consultation with a neurologist is recommended. Care should be exercised when giving these drugs to patients with a history of recurring or chronic infections as they are at an increased risk of infections. Do not start therapy in patients with an active infection.

  2 sources

  1. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline (2009):
  2. "Product Information. Gazyva (obinutuzumab)." Genentech (2013):

• Tumor Lysis Syndrome

  Major

  Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS. Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion. It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS. Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.

  8 sources

  1. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline (2009):
  2. "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc (2011):
  3. "Product Information. Gazyva (obinutuzumab)." Genentech (2013):
  4. "Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc (2014):
  5. "Product Information. Blincyto (blinatumomab)." Amgen USA (2014):
  6. "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb (2014):
  7. "Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation (2015):
  8. "Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb (2015):

• Pancytopenia

  Moderate

  Severe neutropenia, thrombocytopenia, and anemia have been documented with the use of anti-CD20 antibodies. Monitor complete blood counts during and after therapy according to clinical guidelines.

  2 sources

  1. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline (2009):
  2. "Product Information. Gazyva (obinutuzumab)." Genentech (2013):

• Pulmonary Heart Disease

  Moderate

  Patients with a prior history of cardiac or pulmonary disease should be closely monitored during and after the infusion of anti-CD20 antibodies as they can increase the risk of presenting a severe and life-threatening infusion reaction. Therapy with these agents should be permanently discontinued in patients presenting any Grade 4 infusion reactions and for those presenting Grade 3, interrupt therapy and institute treatment according to clinical guidelines. The rate of infusion should be reduced for those patients presenting Grade 1, or 2 reactions.

  2 sources

  1. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline (2009):
  2. "Product Information. Gazyva (obinutuzumab)." Genentech (2013):